InnoCan Pharma

Company Overview

Snapshot

Founded in October 2017 by Ron Mayron, Iris Bincovich, Nir Avram, and Yoram Drucker, InnoCan Pharma operates with 11–50 employees. The company has raised a total of $23.67 million across 13 funding rounds from 4 investors. In October 2021, InnoCan Pharma Corporation announced an C$8.2 million private placement with institutional investors.

Business overview

InnoCan Pharma is a pharmaceutical technology company focused on developing cannabinoid-integrated pharmaceutical products and consumer wellness solutions. Its Pharmaceuticals segment develops innovative drug delivery platforms, including the LPT CBD-loaded liposome platform for prolonged CBD release, currently in preclinical trials for epilepsy and pain management, and the CLX CBD-loaded exosomes platform targeting the central nervous system for regeneration and inflammation. The Consumer Wellness segment develops and markets a portfolio of self-care products, including through a joint venture, BI Sky Global Ltd., which focuses on advanced targeted online sales. The company operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology, Drug Delivery, and Medical Cannabis.

Strategic signal

In September 2024, InnoCan Pharma advanced its Liposomal CBD program, receiving a positive response from the FDA following a successful Pre-IND meeting. This development is a significant regulatory validation for its LPT CBD-loaded liposome platform, signaling progress towards clinical trials and potential market entry for cannabinoid-based therapies in the pharmaceutical industry.

Company Intelligence Q&A

What was a key regulatory milestone for InnoCan Pharma in 2024?

In September 2024, InnoCan Pharma received a positive response from the FDA following a successful Pre-IND meeting regarding its Liposomal CBD program, advancing its drug development efforts.

What was a notable partnership announced by InnoCan Pharma in 2025?

In September 2025, InnoCan Pharma partnered with a sanctuary for injured animals to provide its LPT-CBD injection, aiming to offer remedy and hope through its cannabinoid-based treatments.

What was the outcome of InnoCan Pharma's LPT-CBD patent application in Japan?

In October 2025, the patent for InnoCan Pharma's Liposomal CBD Injection Technology (LPT-CBD) was allowed in Japan, strengthening the company's intellectual property in a key international market.

What was a significant finding regarding InnoCan Pharma's LPT-CBD in October 2024?

In October 2024, InnoCan Pharma's LPT-CBD demonstrated long-term success in relieving osteoarthritis pain in dogs, indicating potential efficacy for its veterinary applications.

When did InnoCan Pharma go public on the CSE?

InnoCan Pharma listed on the Canadian Securities Exchange (CSE) in September 2019.